Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 23, 2022

View Archived Issues

Blockade of HIF-1 leads to ROS overproduction in diabetes

MZE-001 shows promising results in murine and canine models of Pompe disease

S-05014, a novel tyrosinase inhibitor with promising anti-Parkinsonian activity

Discovery of novel peptides as probes for crotamine

Ideaya Biosciences presents POLQ inhibitors

U.S. researchers divulge CDK19 inhibitors

Columbia University discloses CD33/CD45 interaction inhibitors

New IRAK and FLT3 inhibitors described by U.S. investigators

Mirati Therapeutics synthesizes new SOS1 inhibitors

New DNA Damage Response Consortium seeks to advance brain cancer research

Microlyse targets VWF and clears microvascular thrombosis

Code Bio and Takeda collaborate on gene therapies for rare diseases

Sema4 and BioSymetrics partner on drug discovery in cardiovascular, rare and neurological diseases

Phio's INTASYL-based antiviral compounds against SARS-CoV-2 enter in vivo testing

Actinium and AVEO collaborate to develop novel Ac-225 ErbB3-targeted radiotherapy

ALPHA-1062 shown to be neuroprotective in rodent model of traumatic brain injury

JBC-1847 proven effective against Staphylococcus aureus infection

Cantargia reports non-GLP toxicology and pharmacokinetic data on CAN-10

Sorrento's STI-9167 shows neutralizing activity against SARS-CoV-2 Omicron variants

Novel target identified for long QT

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.